Jun 23, 2026
By Transpire Insight
The global nucleic acid amplification testing market involves the global market for diagnostic tests that identify and amplify genetic material (DNA or RNA) of pathogens, genetic diseases, or any other biological entities. Methods like PCR, RT-PCR, isothermal amplification, and next-generation nucleic acid amplification technologies have been widely adopted owing to their high levels of sensitivity, accuracy, and faster results. Some of the growth factors in the Nucleic Acid Amplification Testing (NAAT) Market are increasing occurrences of infections, rising need for molecular diagnostics, development of personalized medicine, and growing trend of point-of-care tests.
25 leading players in the nucleic acid amplification testing market are Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, QIAGEN, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, Hologic, bioMérieux, and Agilent Technologies. They are concentrating on molecular diagnostic platforms, PCR technologies, automation, and rapid test kits in order to gain a competitive edge in the NAAT market.
The following blog highlights the list of Top 25 companies in the Nucleic Acid Amplification Testing Market across the globe. The list provides valuable insights for manufacturers, investors, procurement professionals, and market researchers seeking to understand the competitive landscape of the rapidly growing Nucleic Acid Amplification Testing Market in 2026.
Roche Diagnostics is a leading global healthcare diagnostics company specializing in in vitro diagnostics, molecular diagnostics, and personalized healthcare solutions. The company develops advanced testing platforms and diagnostic assays used for infectious diseases, oncology, genetic disorders, and precision medicine applications.
Founded: 1896 | Headquarters: Basel, Switzerland
Why It Ranks:
Roche Diagnostics ranks among the top companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its strong PCR technology expertise, extensive molecular diagnostics portfolio, high-throughput testing systems, and global presence. The company’s advanced automation capabilities and reliable diagnostic solutions make it a preferred choice among clinical laboratories and healthcare providers.
Regional Dominance:
Roche Diagnostics has a strong market presence across North America, Europe, and Asia-Pacific, with widespread adoption of its molecular diagnostic systems in hospitals, research centers, and diagnostic laboratories. The company continues to expand its footprint in emerging markets through strategic partnerships and healthcare investments.
Product Line:
Roche Diagnostics offers a comprehensive product portfolio including cobas 6800 and cobas 8800 Molecular Systems, cobas PCR assays, infectious disease testing solutions, oncology molecular diagnostics, companion diagnostics, and genetic testing platforms.
Recent Development:
Roche Diagnostics continues to advance its NAAT capabilities through automation, digital laboratory integration, and development of next-generation molecular testing solutions. The company is focusing on expanding multiplex testing, improving turnaround times, and supporting precision medicine through innovative diagnostic technologies.
Abbott Laboratories is a global healthcare company specializing in diagnostics, medical devices, nutrition, and pharmaceuticals. Its diagnostics division provides advanced molecular testing solutions, including nucleic acid amplification technologies used for infectious disease detection and rapid molecular diagnostics.
Founded: 1888 | Headquarters: Abbott Park, Illinois, United States
Why It Ranks:
Abbott ranks among the leading companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its strong molecular diagnostics portfolio, rapid testing capabilities, global healthcare presence, and widespread adoption of its diagnostic platforms in hospitals, laboratories, and point-of-care settings.
Regional Dominance:
Abbott has a strong presence in North America, Europe, and Asia-Pacific, supported by an extensive distribution network and partnerships with healthcare organizations. The company is also expanding its molecular diagnostics reach in emerging markets through affordable and accessible testing solutions.
Product Line:
Abbott offers a comprehensive product portfolio including Alinity m molecular diagnostic systems, ID NOW rapid molecular testing platforms, RealTime PCR assays, infectious disease testing solutions, and laboratory automation technologies for accurate and efficient disease detection.
Recent Development:
Abbott continues to expand its molecular diagnostics capabilities through innovations in rapid testing, automation, and multiplex detection technologies. The company has focused on improving point-of-care molecular testing solutions and strengthening its diagnostic ecosystem to support faster clinical decision-making.
Thermo Fisher Scientific is a global leader in life sciences, analytical technologies, and molecular diagnostics, providing innovative instruments, reagents, and laboratory solutions. The company supports nucleic acid amplification testing through advanced PCR technologies, molecular biology products, and diagnostic workflows used in clinical, research, and biotechnology applications.
Founded: 2006 | Headquarters: Waltham, Massachusetts, United States
Why It Ranks:
Thermo Fisher Scientific ranks among the top companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its extensive PCR technology portfolio, strong research and development capabilities, broad customer base, and leadership in molecular biology reagents and testing solutions. Its scalable solutions serve hospitals, laboratories, pharmaceutical companies, and research institutions worldwide.
Regional Dominance:
Thermo Fisher Scientific has a strong presence in North America, Europe, and Asia-Pacific, supported by a global supply chain, extensive distribution network, and partnerships with healthcare and research organizations. The company is also expanding molecular diagnostics adoption in emerging markets.
Product Line:
Thermo Fisher Scientific offers a wide range of products including Applied Biosystems PCR systems, QuantStudio real-time PCR platforms, TaqMan assays, nucleic acid extraction solutions, molecular biology reagents, and diagnostic testing workflows for infectious diseases, genetic analysis, and research applications.
Recent Development:
Thermo Fisher Scientific continues to strengthen its molecular diagnostics portfolio through advancements in PCR automation, next-generation assay development, integrated sample-to-answer solutions, and expansion of molecular testing technologies for clinical and research applications.
Download Sample Copy of Nucleic Acid Amplification Testing Market: https://www.transpireinsight.com/request-sample/3205
QIAGEN is a global leader in molecular diagnostics and life science research, specializing in sample preparation technologies, nucleic acid purification, PCR-based testing, and molecular analysis solutions. The company provides diagnostic platforms and workflows used for infectious disease detection, oncology testing, and genetic research.
Founded: 1984 | Headquarters: Venlo, Netherlands
Why It Ranks:
QIAGEN ranks among the leading companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its strong expertise in molecular biology, advanced PCR and sample preparation technologies, broad diagnostic assay portfolio, and strong presence in clinical laboratories and research institutions. Its focus on precision diagnostics and automation strengthens its market position.
Regional Dominance:
QIAGEN has a strong presence across Europe, North America, and Asia-Pacific, supported by a global distribution network and collaborations with healthcare providers, academic institutions, and biotechnology companies. The company is expanding its footprint in emerging markets through innovative molecular diagnostic solutions.
Product Line:
QIAGEN offers a comprehensive product portfolio including QIAsymphony automated sample preparation systems, QIAcube instruments, QuantiFERON diagnostic tests, PCR and real-time PCR assays, syndromic testing solutions, nucleic acid extraction kits, and molecular research reagents.
Recent Development:
QIAGEN continues to enhance its molecular diagnostics capabilities through expansion of syndromic testing platforms, development of advanced PCR-based assays, integration of automation technologies, and investment in precision medicine and digital molecular testing solutions.
Danaher Corporation is a global science and technology company with a strong presence in life sciences, diagnostics, and biotechnology. Through its operating companies, Danaher provides advanced molecular diagnostic platforms, automation solutions, and genomic technologies that support nucleic acid amplification testing, infectious disease detection, and precision medicine.
Founded: 1969 | Headquarters: Washington, D.C., United States
Why It Ranks:
Danaher ranks among the top companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its strong diagnostics portfolio, advanced molecular testing technologies, global laboratory network, and innovation capabilities. Its businesses provide high-performance PCR, genomic analysis, and automated diagnostic solutions widely adopted by healthcare providers and research institutions.
Regional Dominance:
Danaher has a strong market presence across North America, Europe, and Asia-Pacific, supported by its extensive global distribution network and healthcare partnerships. The company continues to expand molecular diagnostics adoption in emerging markets through advanced laboratory solutions and strategic investments.
Product Line:
Danaher offers a broad product portfolio including Cepheid GeneXpert molecular diagnostic systems, Hologic molecular testing solutions, Beckman Coulter diagnostic platforms, genomic analysis technologies, PCR-based assays, automated laboratory instruments, and molecular research solutions.
Recent Development:
Danaher continues to strengthen its molecular diagnostics capabilities through investments in precision medicine, automated testing platforms, advanced assay development, and expansion of rapid molecular diagnostic solutions. The company is focusing on improving workflow efficiency, increasing testing accessibility, and supporting next-generation healthcare diagnostics.
Becton Dickinson and Company (BD) is a global medical technology company specializing in diagnostic systems, medical devices, and laboratory solutions. The company supports nucleic acid amplification testing through advanced molecular diagnostic platforms, specimen collection technologies, and automated laboratory workflows used for infectious disease detection and clinical diagnostics.
Founded: 1897 | Headquarters: Franklin Lakes, New Jersey, United States
Why It Ranks:
BD ranks among the leading companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its strong diagnostic technology portfolio, global healthcare presence, extensive laboratory partnerships, and expertise in molecular testing solutions. The company’s focus on automation, rapid diagnostics, and integrated healthcare workflows strengthens its competitive position.
Regional Dominance:
BD has a strong presence in North America, Europe, and Asia-Pacific, with widespread adoption of its diagnostic solutions in hospitals, clinical laboratories, and healthcare facilities. The company continues to expand in emerging markets through strategic partnerships and healthcare infrastructure development.
Product Line:
Becton Dickinson offers a comprehensive product portfolio including BD MAX Molecular Diagnostics System, BD COR System, BD Veritor rapid diagnostic platforms, molecular assays for infectious diseases, specimen collection systems, and automated laboratory solutions.
Recent Development:
BD continues to enhance its molecular diagnostics portfolio through advancements in automated testing systems, expansion of infectious disease assay capabilities, and development of integrated diagnostic solutions that improve testing speed, accuracy, and laboratory efficiency.
Bio-Rad Laboratories is a global life science research and diagnostics company specializing in clinical diagnostics, biotechnology research products, and molecular testing solutions. The company provides advanced PCR, digital PCR, and laboratory technologies that support infectious disease detection, genetic testing, and biomedical research.
Founded: 1952 | Headquarters: Hercules, California, United States
Why It Ranks:
Bio-Rad ranks among the leading companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its strong expertise in PCR technologies, innovative molecular diagnostic platforms, high-quality reagents, and extensive customer base across clinical laboratories and research institutions. Its leadership in digital PCR and molecular biology solutions enhances its competitive position.
Regional Dominance:
Bio-Rad has a strong presence across North America, Europe, and Asia-Pacific, supported by a global sales network, research collaborations, and partnerships with healthcare organizations. The company continues to expand its molecular diagnostics footprint in emerging markets through advanced testing solutions.
Product Line:
Bio-Rad offers a comprehensive product portfolio including CFX real-time PCR systems, QX200 Droplet Digital PCR platforms, PCR reagents, infectious disease molecular assays, nucleic acid amplification solutions, quality control products, and laboratory research instruments.
Recent Development:
Bio-Rad continues to advance its molecular diagnostics portfolio through innovations in digital PCR technology, development of highly sensitive molecular assays, expansion of infectious disease testing solutions, and integration of automated workflows to improve diagnostic accuracy and efficiency.
Hologic is a global medical technology company focused on women’s health, diagnostics, and molecular testing solutions. The company is a major provider of nucleic acid amplification testing technologies, offering advanced molecular diagnostic platforms for infectious disease detection and women’s health applications.
Founded: 1985 | Headquarters: Marlborough, Massachusetts, United States
Why It Ranks:
Hologic ranks among the leading companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its advanced molecular diagnostic expertise, strong presence in women’s health testing, highly sensitive assay technologies, and widespread adoption of its automated molecular platforms in clinical laboratories worldwide.
Regional Dominance:
Hologic has a strong presence in North America and Europe, with growing adoption across Asia-Pacific and other emerging markets. The company’s extensive laboratory partnerships and global distribution network support the expansion of its molecular diagnostic solutions.
Product Line:
Hologic offers a comprehensive product portfolio including Panther System, Panther Fusion System, Aptima molecular assays, Aptima Combo 2 Assay for sexually transmitted infections, respiratory disease testing solutions, and automated molecular diagnostic platforms.
Recent Development:
Hologic continues to expand its molecular diagnostics capabilities through advancements in automated testing platforms, development of multiplex molecular assays, and expansion of infectious disease and women’s health diagnostic solutions to improve early detection and clinical outcomes.
bioMérieux is a global leader in in vitro diagnostics, specializing in clinical diagnostics, molecular testing, microbiology, and infectious disease solutions. The company develops advanced diagnostic platforms that enable rapid and accurate detection of pathogens through nucleic acid amplification and syndromic testing technologies.
Founded: 1963 | Headquarters: Marcy-l'Étoile, France
Why It Ranks:
bioMérieux ranks among the leading companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its strong expertise in infectious disease diagnostics, innovative molecular platforms, extensive microbiology portfolio, and widespread use of its testing solutions in hospitals and clinical laboratories. Its focus on rapid pathogen identification strengthens its market position.
Regional Dominance:
bioMérieux has a strong presence across Europe, North America, and Asia-Pacific, supported by a global sales network, healthcare partnerships, and advanced diagnostic laboratory solutions. The company continues to expand its presence in emerging markets through investments in infectious disease testing infrastructure.
Product Line:
bioMérieux offers a comprehensive product portfolio including BIOFIRE FilmArray molecular diagnostic systems, BIOFIRE multiplex PCR panels, VITEK microbial identification systems, molecular assays for infectious diseases, microbiology testing solutions, and automated laboratory diagnostic platforms.
Recent Development:
bioMérieux continues to strengthen its molecular diagnostics portfolio through expansion of multiplex PCR testing, development of advanced syndromic testing solutions, digital integration of diagnostic workflows, and investments in rapid infectious disease detection technologies.
Agilent Technologies is a global leader in life sciences, diagnostics, and analytical technologies, providing advanced solutions for molecular biology, genomics, and laboratory testing. The company offers innovative instruments, reagents, and workflows that support nucleic acid analysis, genetic testing, and research applications.
Founded: 1999 | Headquarters: Santa Clara, California, United States
Why It Ranks:
Agilent Technologies ranks among the leading companies in the Nucleic Acid Amplification Testing (NAAT) Market due to its strong expertise in molecular analysis, high-performance laboratory technologies, advanced genomics solutions, and extensive presence across research and diagnostic laboratories. The company’s focus on precision testing and innovation strengthens its market position.
Regional Dominance:
Agilent Technologies has a strong presence in North America, Europe, and Asia-Pacific, supported by a global distribution network, research collaborations, and partnerships with healthcare and biotechnology organizations. The company continues to expand its molecular diagnostics presence in emerging markets.
Product Line:
Agilent Technologies offers a comprehensive product portfolio including SureSelect target enrichment solutions, AriaMx and AriaDx real-time PCR systems, genomic analysis platforms, nucleic acid preparation products, molecular biology reagents, and laboratory workflow solutions for diagnostics and research applications.
Recent Development:
Agilent Technologies continues to enhance its molecular diagnostics capabilities through advancements in genomics, automation, precision medicine technologies, and integrated laboratory solutions. The company is focusing on expanding molecular testing applications and developing innovative tools for genetic analysis and clinical research.
Complete Top 25 Rankings - Nucleic Acid Amplification Testing Market
Future Opportunities:
|
Opportunity Area |
Growth Potential |
|
Point-of-care NAAT devices |
Rising need for speedy tests in hospitals, clinics, and even remote healthcare facilities. |
|
Multiplex molecular diagnostics |
Ability to detect many pathogens at once and increase test efficiency. |
|
Personalized medicine applications |
Increased usage of genetic tests and biomarkers in managing diseases. |
|
Emerging market expansion |
Developing countries investing more in their healthcare infrastructure. |
Conclusion:
The Nucleic Acid Amplification Testing Market is projected to grow rapidly owing to increasing demands for fast and accurate molecular diagnostics. Increasing infectious disease monitoring, advancements in portable testing equipment, and increased use in personalized medicine will offer great opportunities in this market in the coming years. Major diagnostic companies are concentrating on automating and multiplexing their products at affordable prices to stay competitive in this fast-growing market.
Send us a brief description of your challenge and we'll get back to you within 24 hours.
inquiry@transpireinsight.com
APAC:+91 7666513636
Address
